Sign in
Taking people in United StatesPhase 1

Tests RP-A701 gene therapy in adults with BAG3 dilated cardiomyopathy

Tests RP-A701, given once through a vein, in adults with BAG3 heart disease.

Key facts

Who runs it
Rocket Pharmaceuticals Inc.
Where
Charleston, Rochester, and San Diego, United StatesSee the 3 sites
Trial code
Registry title
A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
Status
Recruiting
Phase
Phase 1
People taking part
8 people, planned
Started
17 Apr 2026
Expected to end
Jun 2029
Type of study
Interventional
Treatments tested
  • RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)
Record updated
1 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 with dilated cardiomyopathy caused by a harmful change in the BAG3 gene. They must also have an ICD and moderate heart failure symptoms.

Age
18 to 65 years
Sex
Men and women
Disease stage
Dilated cardiomyopathy with mild to moderate weakness of the heart's pumping (LVEF 25% to 45%) and NYHA Class II or III heart failure symptoms on a stable heart failure treatment for 30 days before joining.
Earlier treatment
An ICD (implanted defibrillator) in place for at least 3 months. No earlier gene transfer or gene editing study.
Biomarker or test result
A documented pathogenic or likely pathogenic variant in the BAG3 gene.

Main reasons for not taking part

  • Heart disease that may come from a genetic cause other than a BAG3 variant
  • Earlier participation in a gene transfer or gene editing study
  • IV inotropic, vasodilator or diuretic treatment in the last 30 days
  • History of a blood clot inside the heart or an arterial blood clot event
  • LVEF below 25%, severe right heart weakness, or NYHA Class I or IV heart failure

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Subjects are eligible for inclusion into the study only if all the following criteria apply:
  • Male or female between 18 and 65 years of age at the time of signing the informed consent
  • Capable of and willing to provide signed informed consent
  • Clinical diagnosis of DCM defined as and requiring each of the following:; Mild to moderate systolic dysfunction (LVEF ≥ 25% and ≤ 45%) by echocardiography or CMR performed within 3 months of enrollment; Absence of severe coronary artery disease (>70% stenosis) or active myocardial ischemia as the etiology of LV systolic dysfunction; Absence of uncontrolled hypertension, significant cardiac valve disease (i.e., greater than moderate in severity), infiltrative disorder, or systemic disease known to cause cardiomyopathy
  • Documentation of a pathogenic or likely pathogenic variant in BAG3
  • History of ICD implantation ≥ 3 months prior to enrollment
  • NYHA Class II or III HF symptoms with stable HF therapeutic guideline-directed medical regimen for 30 days prior to enrollment

Who cannot take part

  • Previous participation in a study of gene transfer or gene editing
  • I.V. inotropic, vasodilator, or diuretic therapy ≤ 30 days prior to enrollment
  • Severe RV dysfunction assessed by echocardiogram or CMR ≤ 12 months prior to screening
  • CV disease that may be related to a genetic etiology other than a BAG3 pathogenic or likely pathogenic variant
  • History of intracardiac thrombosis or arterial thromboembolic events
  • LVEF < 25% by echocardiogram or CMR at ≤ 3 months prior to screening
  • NYHA Class I or IV HF

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Medical University of South CarolinaCharleston, United StatesContact: Clinical ResTaking people
  • Mayo ClinicRochester, United StatesContact: Clinical Research CoordinatorTaking people
  • University of California San DiegoSan Diego, United StatesContact: Clinical Research CoordinatorTaking people

About the trial

What the trial wants to find out

This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.

The group in the trial

  • Single ascending dose of RP-A701 in up to 2 consecutive cohortsTreatment being tested

    Participants will receive a single intravenous dose of RP-A701 on Day 0 and will be followed for up to two years

    Treatment: RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human BCL2-associated Athanogene 3 (BAG3) Gene Coding Sequence (RP-A701) in Subjects With Dilated Cardiomyopathy Arising From Pathogenic BAG3 Variants (BAG3-DCM)
Plain-language title
Tests RP-A701 gene therapy in adults with BAG3 dilated cardiomyopathyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07137338, who can take part
Record updated
1 October 2026